JP2019532657A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532657A5
JP2019532657A5 JP2019522512A JP2019522512A JP2019532657A5 JP 2019532657 A5 JP2019532657 A5 JP 2019532657A5 JP 2019522512 A JP2019522512 A JP 2019522512A JP 2019522512 A JP2019522512 A JP 2019522512A JP 2019532657 A5 JP2019532657 A5 JP 2019532657A5
Authority
JP
Japan
Prior art keywords
item
polypeptide
lnp
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532657A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058585 external-priority patent/WO2018081459A1/en
Publication of JP2019532657A publication Critical patent/JP2019532657A/ja
Publication of JP2019532657A5 publication Critical patent/JP2019532657A5/ja
Priority to JP2022143786A priority Critical patent/JP2022184924A/ja
Pending legal-status Critical Current

Links

JP2019522512A 2016-10-26 2017-10-26 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法 Pending JP2019532657A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022143786A JP2022184924A (ja) 2016-10-26 2022-09-09 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662412933P 2016-10-26 2016-10-26
US62/412,933 2016-10-26
US201762467034P 2017-03-03 2017-03-03
US62/467,034 2017-03-03
US201762490522P 2017-04-26 2017-04-26
US62/490,522 2017-04-26
US201762558206P 2017-09-13 2017-09-13
US62/558,206 2017-09-13
PCT/US2017/058585 WO2018081459A1 (en) 2016-10-26 2017-10-26 Messenger ribonucleic acids for enhancing immune responses and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143786A Division JP2022184924A (ja) 2016-10-26 2022-09-09 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法

Publications (2)

Publication Number Publication Date
JP2019532657A JP2019532657A (ja) 2019-11-14
JP2019532657A5 true JP2019532657A5 (cg-RX-API-DMAC7.html) 2020-12-03

Family

ID=60570181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522512A Pending JP2019532657A (ja) 2016-10-26 2017-10-26 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法
JP2022143786A Pending JP2022184924A (ja) 2016-10-26 2022-09-09 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022143786A Pending JP2022184924A (ja) 2016-10-26 2022-09-09 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法

Country Status (13)

Country Link
US (3) US20180311343A1 (cg-RX-API-DMAC7.html)
EP (1) EP3532070A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019532657A (cg-RX-API-DMAC7.html)
KR (1) KR20190086681A (cg-RX-API-DMAC7.html)
CN (1) CN110402145A (cg-RX-API-DMAC7.html)
AU (1) AU2017347837A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019008369A2 (cg-RX-API-DMAC7.html)
CA (1) CA3042015A1 (cg-RX-API-DMAC7.html)
IL (1) IL266222A (cg-RX-API-DMAC7.html)
MX (1) MX2019004810A (cg-RX-API-DMAC7.html)
RU (1) RU2765874C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201903674YA (cg-RX-API-DMAC7.html)
WO (1) WO2018081459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
CA3050914A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3052255A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
WO2019035901A1 (en) * 2017-08-15 2019-02-21 University Of Miami COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
CN112673106A (zh) 2017-12-21 2021-04-16 贝瑟克里科有限公司 点击修饰的mRNA
WO2019143948A1 (en) * 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019191070A1 (en) * 2018-03-26 2019-10-03 University Of Miami Recombinant viral vector and uses thereof
US20210163928A1 (en) * 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
CN118436618A (zh) * 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020028743A1 (en) * 2018-08-03 2020-02-06 Board Of Trustees Of Michigan State University Compositions of sting variants, combinations thereof, and methods for inducing and enhancing an immune response against infections, diseases, and disorders
WO2020041691A1 (en) * 2018-08-24 2020-02-27 City Of Hope Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020132196A1 (en) * 2018-12-21 2020-06-25 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
CN109762895A (zh) * 2019-01-07 2019-05-17 中国医学科学院北京协和医院 miR-146a在制备诊断激素性股骨头坏死产品中的应用
EP3683229A1 (en) * 2019-01-21 2020-07-22 Charité - Universitätsmedizin Berlin Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP3946434A1 (en) 2019-04-02 2022-02-09 Immunetune B.V. Immune-stimulatory compositions and use thereof
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状rna組成物及び方法
WO2021000013A1 (en) * 2019-07-03 2021-01-07 The Walter And Eliza Hall Institute Of Medical Research Compositions and methods of use
US11666624B2 (en) 2019-09-24 2023-06-06 Auburn University Phage-peptide constructs for stimulating an immune response against CD47
EP4529928A3 (en) * 2019-10-09 2025-05-28 Translate Bio, Inc. Compositions, methods and uses of messenger rna
US12618839B2 (en) 2019-10-24 2026-05-05 Arizona Board Of Regents On Behalf Of Arizona State University Antibodies for detecting Epstein Barr virus-positive gastric cancer
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
KR20220100664A (ko) * 2019-11-14 2022-07-15 보가지치 유니버시테시 암 면역요법에서의 asc speck
US20220409540A1 (en) * 2019-11-15 2022-12-29 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating hpv mrna
US20210154281A1 (en) * 2019-11-26 2021-05-27 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
MX2022006854A (es) * 2019-12-04 2022-11-30 Orna Therapeutics Inc Composiciones y metodos de arn circular.
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
WO2021168266A1 (en) * 2020-02-21 2021-08-26 Temple University - Of The Commonwealth System Of Higher Education Eradication of merkel cell polyomavirus
JP7539723B2 (ja) * 2020-02-21 2024-08-26 コンバインド セラピューティクス インコーポレイテッド コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
BR112022021380A2 (pt) 2020-04-22 2022-12-06 Nutcracker Therapeutics Inc Nanopartículas de rna mensageiro para tratamento
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
CN116096906A (zh) * 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
JP2023536844A (ja) * 2020-07-31 2023-08-30 コンバインド セラピューティクス インコーポレイテッド ワクチン接種を改善するための組成物および方法
IL300026A (en) * 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
EP4228679A1 (en) * 2020-10-14 2023-08-23 Rnaimmune, Inc. Pan-ras mrna cancer vaccines
GB202017119D0 (en) * 2020-10-28 2020-12-09 Oxford Vacmedix Uk Ltd Polypeptides for cancer treatment
JP7829242B2 (ja) * 2020-11-20 2026-03-13 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
GB202020063D0 (en) * 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
WO2022140588A1 (en) * 2020-12-23 2022-06-30 Kernal Biologics, Inc. Constitutively active payloads
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
CA3204730A1 (en) * 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4313109A1 (en) * 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022244815A1 (ja) * 2021-05-19 2022-11-24 第一三共株式会社 Hpv感染症ワクチン
US20240269267A1 (en) * 2021-06-03 2024-08-15 The Wistar Institute Of Anatomy And Biology Synthetic dna vaccine immunogenic improvements
CN117915946A (zh) * 2021-07-06 2024-04-19 宾夕法尼亚大学理事会 用于丙型肝炎病毒的含P7的核苷修饰mRNA-脂质纳米颗粒谱系疫苗
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN113616793B (zh) * 2021-08-20 2023-07-04 南方海洋科学与工程广东省实验室(湛江) Traf6抑制剂在作为和/或制备铁死亡诱导剂中的应用
WO2023076131A2 (en) * 2021-10-25 2023-05-04 The Regents Of The University Of California Kaposi sarcoma associated herpesvirus gene function
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN113952359A (zh) * 2021-11-19 2022-01-21 大连理工大学盘锦产业技术研究院 顺铂与Tri-1的联合抗肺癌药物组合物及其应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023125974A1 (zh) * 2021-12-31 2023-07-06 广州国家实验室 mRNA疫苗
JP2025504430A (ja) * 2022-01-17 2025-02-12 サノフイ 脂質化合物及びその使用
EP4479085A1 (en) * 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
CN114627970A (zh) * 2022-03-15 2022-06-14 中南大学湘雅医院 结肠腺癌的焦亡相关lncRNA预后模型及其构建方法和应用
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115089588A (zh) * 2022-08-22 2022-09-23 云南大学 达沙布韦作为e3连接酶新型配体构建protac的应用
WO2024153000A1 (en) * 2023-01-17 2024-07-25 The University Of Hong Kong Cancer immunotherapy by delivery of mrna
CN116716326A (zh) * 2023-02-03 2023-09-08 南方科技大学 一种乙型肝炎mRNA及其疫苗与用途
WO2025087266A1 (en) * 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Immunomodulatory mrna cassettes, and uses thereof
WO2025087250A1 (en) * 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Therapeutic mrna cancer vaccine targeting hpv-associated cancers
US20250177432A1 (en) * 2023-12-04 2025-06-05 Wuhan Houxian Biopharmaceutical Co. Ltd. Rna molecules and compositions for cancer immunotherapy
CN121464216A (zh) * 2024-01-17 2026-02-03 艾博生物科技(上海)有限公司 用于诱导针对kras突变细胞的抗原特异性免疫的组合物和方法
WO2025189435A1 (zh) * 2024-03-14 2025-09-18 北京合生基因科技有限公司 针对猫fipv的多表位抗原构建rna疫苗的方法
WO2025212374A1 (en) * 2024-04-02 2025-10-09 The General Hospital Corporation Methods for utilizing commensal polyomavirus for cancer therapy
WO2025246436A1 (en) * 2024-05-29 2025-12-04 Therorna Inc. Circular rna-based therapeutic vaccine for treating hpv positive cancer
WO2025264648A2 (en) * 2024-06-17 2025-12-26 Grann Pharmaceuticals Inc. Compositions and methods for modulating native human mrna expression
CN118839285B (zh) * 2024-08-05 2025-03-18 洛阳莱普生信息科技有限公司 基于智能耳标的畜牧生物资产监管方法及系统
WO2026056860A1 (zh) * 2024-09-10 2026-03-19 北京剂泰生命科技有限公司 用于递送hpv核酸疫苗的脂质纳米颗粒

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN101622348A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
EP2225396A4 (en) 2007-11-30 2011-03-02 Univ Ohio State Res Found PROFILING AND SCREENING OF MICRO-RNA EXPRESSION IN PERIPHERAL BLOOD IN LUNG CANCER
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
JP2011517932A (ja) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病(ccl)と関連するマイクロrnaシグネチャーおよびその使用
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009149539A1 (en) * 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
US20120264626A1 (en) 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9862968B2 (en) * 2010-10-26 2018-01-09 Friedrich-Alexander-Universität Erlangen-Nürnberg NF-κB signaling pathway-manipulated dendritic cells
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
EP2694534B1 (en) 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
JP5965481B2 (ja) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ 皮膚t細胞リンパ腫(ctcl)の診断用マイクロrnaプロファイリング
WO2013033640A1 (en) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
US20140243240A1 (en) 2011-10-26 2014-08-28 Georgetown University microRNA EXPRESSION PROFILING OF THYROID CANCER
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
CA2865620A1 (en) 2012-03-05 2013-09-12 University Of Maryland, Baltimore Multivalent vaccine protection from staphylococcus aureus infection
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10093701B2 (en) * 2012-09-07 2018-10-09 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP3077820B1 (en) 2013-12-03 2025-02-26 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
HRP20220070T1 (hr) * 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
CA2947963A1 (en) 2014-05-06 2015-11-12 Targovax Asa Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
CA2953341C (en) * 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂

Similar Documents

Publication Publication Date Title
TWI860474B (zh) 冠狀病毒疫苗
EP2127671B1 (en) Therapeutic agent for cancer
RU2019116006A (ru) Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
US20220241428A1 (en) Macrophage specific engager compositions and methods of use thereof
US20250345417A1 (en) Compositions and methods for treatment of melanoma
CN109045289A (zh) 疫苗接种和抑制pd-1途径的组合
US20250312428A1 (en) Heterologous Prime Boost Vaccine
JP2026503718A (ja) エプスタイン・バーウイルスmRNAワクチン
JP2022533717A (ja) 卵巣癌のための治療用rna
JP2025179041A (ja) 帯状疱疹mRNAワクチン及びその調製方法と使用
AU2004266034A1 (en) In vivo targeting of dendritic cells
JP2023554155A (ja) 癌を治療するための治療用rna
CN118369111A (zh) 单纯疱疹病毒mRNA疫苗
CN118450902A (zh) 诺如病毒疫苗及使用方法
WO2024131833A1 (en) Mrna-based hpv+ cancer vaccines, and uses thereof
WO2023077924A1 (zh) 一种抗胰腺癌的疫苗、及其医药用途
CN118695850A (zh) 通用流感疫苗及使用方法
US20240115675A1 (en) Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
US20220305099A1 (en) Methods for inducing an immune response against neoantigens
US20250000971A1 (en) Tlr4 agonist for modulating immune response
TWI920113B (zh) 脂質奈米粒子
JP7668549B2 (ja) がん免疫療法におけるascスペック
RU2785954C2 (ru) Конструкты т-клеточного рецептора и их применение
HK40099663A (en) Therapeutic rna for treating cancer
WO2023056337A1 (en) Tlr8 agonist for modulating immune response